News summary

Evaluation of cardiovascular risk using smartwatch-measured pulse wave velocity in China: a nationwide cross-sectional study

Source: Frontiers - Health • Published: 28 Sept 2026, 00:00

Summarized by Masters of Longevity from Frontiers - Health.

Smartwatch-measured pulse wave velocity: a nationwide study-style article examining how wearable data can be used to assess arterial stiffness and cardiovascular risk.

Evaluation of cardiovascular risk using smartwatch-measured pulse wave velocity in China: a nationwide cross-sectional study
Key Takeaways
  • The study used smartwatch-derived pulse wave velocity to estimate arterial stiffness across a nationwide Chinese cohort.
  • Previous validation showed smartwatch cfPWV agreed with Complior reference, with concordance 0.9045 and mean absolute error 0.66 m/s.
Read the full article at Frontiers - Health ↗

Continue exploring

Recommended MoL Picks

MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.